The DOI matches its Crossref record; 265 of the 265 references it cites were found in a registry or an index.
Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process
Open accessAbstract
Multiple Myeloma (Mm) is a clonal B-cell neoplasm that affects terminally differentiated B cells (ie, plasma cells) and may proceed through different phases: an inactive phase in which tumor cells are nonproliferating mature plasma cells, an active phase with a small percentage (<1%) of proliferating plasmablastic cells, and a fulminant phase with the frequent occurrence of extramedullary proliferation and an increase in plasmablastic cells. During the past years, considerable progress has been made in identifying some of the critical components of neoplastic transformation in MM. This review intends to propose a model of a stepwise malignant transformation during MM pathogenesis. Both diagnostic and therapeutic implications of this model will be discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–265 of 265
Rare occurrence of P53 gene mutations in multiple myeloma
Preudhomme, C., Facon, T. T. F., Zandecki, M., Vanrumbeke, M., Laı̈, J. L., Nataf, E., Loucheux‐Lefebvre, M. H., Kerckaert, J. P., & Fenaux, P. (1992) · British Journal of Haematology · doi:10.1111/j.1365-2141.1992.tb08253.x · Cited by 73
Hallek, M. J., Neumann, C., Schäffer, M., Danhauser-riedl, S., von Bubnoff, N. C. C., de Vos, G., Druker, B. J., Yasukawa, K., Griffin, J. D., & Emmerich, B. (1997) · PubMed · Cited by 73
Self-citationVerfaillie, C. M., Hurley, R., Lundell, B. I., Zhao, C., & Bhatia, R. (2009) · Acta Haematologica · doi:10.1159/000203658 · Cited by 69
Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death.
Demartis, A., Bernassola, F., Savino, R., Melino, G., & Ciliberto, G. (1996) · PubMed · Cited by 66
IL-6 receptor and mechanism of signal transduction
Kishimoto, T., Akira, S., & Taga, T. (1992) · International Journal of Immunopharmacology · doi:10.1016/0192-0561(92)90173-i · Cited by 64
Interleukin-4 inhibits growth of multiple myelomas by suppressing interleukin-6 expression.
Herrmann, F., Andreeff, M., Gruss, H. J., Brach, M. A., Lübbert, M., & Mertelsmann, R. (1991) · PubMed · Cited by 63
Schieven, G. L., Kallestad, J. C., Brown, T. J., Ledbetter, J. A., & Linsley, P. S. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.149.5.1676 · Cited by 62
Ogata, A., Chauhan, D., Urashima, M., Teoh, G., Treon, S. P., & Anderson, K. C. (1997) · PubMed · Cited by 61
Self-citationGrossman, A., Mittrücker, H.-W., Nicholl, J., Suzuki, A., Chung, S., Antonio, L., Suggs, S., Sutherland, G. R., Siderovski, D. P., & Mak, T. W. (1996) · Genomics · doi:10.1006/geno.1996.0547 · Cited by 60
Expression of the retinoblastoma protein in low-grade B-cell lymphoma: relationship to cyclin D1
Zukerberg, L., Benedict, W. F., Arnold, A., Dyson, N. J., Harlow, E. E., & Harris, N. L. (1996) · Blood · doi:10.1182/blood.v88.1.268.268 · Cited by 59
Ishikawa, H., Tanaka, H., Iwato, K., Tanabe, O., Asaoku, H., Nobuyoshi, M., Yamamoto, I., Kawano, M., & Kuramoto, A. (1990) · Blood · doi:10.1182/blood.v75.3.715.715 · Cited by 59
Generation of a fusion partner to sample the repertoire of splenic B cells destined for apoptosis.
Ray, S., & Diamond, B. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.12.5548 · Cited by 56
AMPLIFICATION OF THEC‐MYCONCOGENE IN HUMAN PLASMA‐CELL LEUKEMIA
Sümegi, J., HEDBERG, T., Björkholm, M., Godal, T., Mellstedt, H., NILSSON, M. G., Perlmann, C., & Klein, G. (1985) · International Journal of Cancer · doi:10.1002/ijc.1985.36.3.367 · Cited by 55
Filella, X., Bladé, J., Guillermo, Á., Molina, R., Rozman, C., & Ballesta, A. M. (1996) · PubMed · Cited by 55
Frequent somatic deletion of the 13q12.3 locus encompassing BRCA2 in chronic lymphocytic leukemia
Garcia-Marco, J. A., Caldas, C., Price, C., Wiedemann, L., Ashworth, A., & Catovsky, D. (1996) · Blood · doi:10.1182/blood.v88.5.1568.1568 · Cited by 53
Non‐random chromosomal aberrations associated with multiple myeloma
Lewis, J. P., & MacKenzie, M. R. (1984) · Hematological Oncology · doi:10.1002/hon.2900020402 · Cited by 52
Schwabe, M., Brini, A. T., Bosco, M. C., Rubboli, F., Egawa, M., Zhao, J., Princler, G. L., & Kung, H. F. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117596 · Cited by 52
Analysis of the p16INK4A, p15INK4B and p18INK4C genes in multiple myeloma
Tasaka, T., Berenson, J. R., Vescio, R. A., Hirama, T., Miller, C. W., Nagai, M., Takahara, J., & Koeffler, H. P. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.8552482.x · Cited by 51
Cellular origin and extent of clonal involvement in multiple myeloma: genetic and phenotypic studies
Takishita, M., Kosaka, M., Goto, T., & Saito, S. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb06732.x · Cited by 50
Oncostatin M induces association of Grb2 with Janus kinase JAK2 in multiple myeloma cells.
Chauhan, D., Kharbanda, S. M., Ogata, A., Urashima, M., Frank, D. A., Malik, N., Kufe, D. W., & Anderson, K. C. (1995) · The Journal of Experimental Medicine · doi:10.1084/jem.182.6.1801 · Cited by 50
Self-citationde Hon, F. D., Ehlers, M., Rose‐John, S., Ebeling, S. B., Bos, H. K., Aarden, L. A., & Brakenhoff, J. P. J. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.180.6.2395 · Cited by 50
Puthier, D., Bataille, R., Barillé‐Nion, S., Mellerin, M., Harousseau, J., Ponzio, A., Robillard, N., Wijdenes, J., & Amiot, M. (1996) · Blood · doi:10.1182/blood.v88.12.4659.bloodjournal88124659 · Cited by 49
IgH Translocations in Multiple Myeloma: A Nearly Universal Event that Rarely Involves c-myc
Bergsagel, P. L., Nardini, E., Brents, L. A., Chesi, M., & Kuehl, W. M. (1997) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-60801-8_30 · Cited by 48
Aberrant translational control of the c-myc gene in multiple myeloma.
Paulin, F., West, M. J., Sullivan, N. F., Whitney, R. L., Lyne, L., & Willis, A. E. (1996) · PubMed · Cited by 48
Oncogenes in multiple myeloma: point mutation of N-ras.
Paquette, R., Berenson, J., Lichtenstein, A., McCormick, F. P., & Koeffler, H. P. (1990) · PubMed · Cited by 47
Serum Levels of Soluble IL-6 Receptor in Multiple Myeloma as Indicator of Disease Activity
Papadaki, H. Α., Kyriakou, D., Foudoulakis, A., Markidou, F., Alexandrakis, M. G., & Eliopoulos, G. D. (2009) · Acta Haematologica · doi:10.1159/000203682 · Cited by 45
Anti-CD40 antibody binding modulates human multiple myeloma clonogenicity in vitro
Tong, A. W., Zhang, B., MUES, G. I., Solano, M., Hanson, T., & Stone, M. (1994) · Blood · doi:10.1182/blood.v84.9.3026.3026 · Cited by 44
Wendtner, C.-M., Nolte, A., Mangold, E., Buhmann, R., Maass, G., Chiorini, J., Winnacker, E.-L., Emmerich, B., Kotin, R. M., & Hallek, M. J. (1997) · Gene Therapy · doi:10.1038/sj.gt.3300447 · Cited by 43
Self-citationAcute phase proteins and prognosis in multiple myeloma
Merlini, G., Perfetti, V., Gobbi, P. G., Quaglini, S., Franciotta, D. M., Marinone, G., & Ascari, E. (1993) · British Journal of Haematology · doi:10.1111/j.1365-2141.1993.tb04696.x · Cited by 42
Nobuyoshi, M., Kawano, M., Tanaka, H., Ishikawa, H., Tanabe, O., Iwato, K., Asaoku, H., Sakai, A., & Kuramoto, A. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.1991.tb08620.x · Cited by 42
Ehlers, M., de Hon, F. D., Bos, H. K., Horsten, U., Kurapkat, G., de Leur, H. S.-V., Grötzinger, J., Wollmer, A., Brakenhoff, J. P. J., & Rose‐John, S. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.14.8158 · Cited by 42
Interferon-β Interrupts Interleukin-6–Dependent Signaling Events in Myeloma Cells
Berger, L., & Hawley, R. G. (1997) · Blood · doi:10.1182/blood.v89.1.261 · Cited by 41
Jernberg‐Wiklund, H., Pettersson, M., & Nilsson, K. (1991) · European Journal Of Haematology · doi:10.1111/j.1600-0609.1991.tb00546.x · Cited by 41
Kreitman, R. J., Siegall, C. B., FitzGerald, D., Epstein, J., Barlogie, B., & Pastan, I. H. (1992) · Blood · doi:10.1182/blood.v79.7.1775.1775 · Cited by 40
Nuclear signaling by interleukin-6
Chen‐Kiang, S., Hsu, W., Natkunam, Y., & Zhang, X. (1993) · Current Opinion in Immunology · doi:10.1016/0952-7915(93)90091-6 · Cited by 40
Adhesion molecules involved in the binding of murine myeloma cells to bone marrow stromal elements
Okada, T., & Hawley, R. G. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910630613 · Cited by 39
Effect of IL-6 receptor antisense oligodeoxynucleotide on in vitro proliferation of myeloma cells.
Keller, E. T., & Ershler, W. B. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.8.4091 · Cited by 36
Müller, J. R., Janz, S., & Potter, M. (1995) · PubMed · Cited by 36
Characterization of p16(INK4A) expression in multiple myeloma and plasma cell leukemia.
Urashima, M., Teoh, G., Ogata, A., et al. (1997) · PubMed · Cited by 35
The Retinoblastoma Gene (RB-1) Status in Multiple Myeloma: A Report on 35 Cases
Zandecki, M., Facon, T. T. F., Preudhomme, C., et al. (1995) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199509059651 · Cited by 35
Akiyama, N., Tsuruta, H., Sasaki, H., Sakamoto, H., Hamaguchi, M., OHMURA, Y., Seto, M., Ueda, R., Hirai, H., & Yazaki, Y. (1994) · PubMed · Cited by 35
In Vitro Growth Of Human Multiple Myeloma: Implications for Biology and Therapy
Caligaris‐Cappio, F., Gregoretti, M. G., Ghia, P., & Bergui, L. (1992) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(18)30343-5 · Cited by 34
Bcl-2 protein expression is not related to short survival in multiple myeloma.
Ong, F., van Nieuwkoop, J. A., de Groot-Swings, G. M., Hermans, J. H., Harvey, M. S., Kluin, P. M., & Kluin‐Nelemans, H. C. (1995) · PubMed · Cited by 34
Neumann, C. A., Zehentmaier, G., Danhauser-Riedl, S., Emmerich, B., & Hallek, M. J. (1996) · European Journal of Immunology · doi:10.1002/eji.1830260217 · Cited by 33
Self-citationLévy, Y., Labaume, S., Colombel, M. C., & Brouet, J. C. (1996) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.1996.d01-637.x · Cited by 32
Interleukin-6 in Multiple Myeloma: Correlation with Disease Activity and Ki-67 Proliferation Index
Thaler, J., Fechner, F. P., Herold, M., & Huber, H. P. (1994) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199409059598 · Cited by 32
Peschel, C., Aulitzky, W. E., & Huber, C. G. (1996) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199609074370 · Cited by 32
Vídriales, M., & Anderson, K. C. (1996) · Molecular Medicine Today · doi:10.1016/1357-4310(96)84846-5 · Cited by 31
Self-citationCorrelations between karyotype and cytologic findings in multiple myeloma.
Weh, H. J., Bartl, R., Seeger, D. R., Selbach, J., Kuse, R., & Hossfeld, D. K. (1995) · PubMed · Cited by 30
The Oncoprotein Phenotype of Plasma Cells from Patients with Multiple Myeloma
Brown, R. D., Pope, B., Luo, X., Gibson, J., & Joshua, D. (1994) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199409114152 · Cited by 30
Interleukin‐10 induces interleukin‐11 responsiveness in human myeloma cell lines
Lu, Z., Gu, Z., Zhang, X., Wijdenes, J., Neddermann, P., Rossi, J., & Klein, B. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)01322-9 · Cited by 30
Fiedler, W., Weh, H. J., & HOSSFELD, D. K. (1992) · British Journal of Haematology · doi:10.1111/j.1365-2141.1992.tb08171.x · Cited by 30
Lee, I.-S., Liu, Y., Narazaki, M., Hibi, M., Kishimoto, T., & Taga, T. (1997) · FEBS Letters · doi:10.1016/s0014-5793(96)01456-1 · Cited by 29
CD40 and the Effect of Anti-CD40-Binding on Human Multiple Myeloma Clonogenicity
Tong, A. W., & Stone, M. J. (1996) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199609067572 · Cited by 29
Willems, P. M. W., Kuypers, A. W. H. M., Meijerink, J. P. P., Holdrinet, R. S. G., & Mensink, E. J. B. M. (1993) · PubMed · Cited by 25
Chadwick, D. E., JEAN, L. F. L., Jamal, N., Messner, H. A., Murphy, J. R., & Minden, M. D. (1993) · British Journal of Haematology · doi:10.1111/j.1365-2141.1993.tb08641.x · Cited by 20
C-kit ligand (SCF) in human multiple myeloma cells
Lemoli, R. M., & Fortuna, A. (1996) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199609052429 · Cited by 20
Phosphorylation of the TAL1 Oncoprotein by the Extracellular-Signal-Regulated Protein Kinase ERK1
Cheng, J., Cobb, M. H., & Baer, R. J. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.2.801-808.1993 · Cited by 20
Therapeutic strategies for inhibition of interleukin-6 mediated multiple myeloma cell growth
Ogata, A., & Anderson, K. C. (1996) · Leukemia Research · doi:10.1016/0145-2126(95)00085-2 · Cited by 19
Self-citationJernberg‐Wiklund, H., Pettersson, M., Larsson, L., Anton, R., & Nilsson, K. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910510121 · Cited by 18
Role of CDK4 and p16INK4A in interleukin-6-mediated growth of multiple myeloma
Urashima, M., Teoh, G. K. H., Ogata, A., Chauhan, D., Treon, S. P., Hoshi, Y., DeCaprio, J. A., & Anderson, K. C. (1997) · Leukemia · doi:10.1038/sj.leu.2400843 · Cited by 17
Self-citationA high frequency of N-RAS oncogene mutations in multiple myeloma.
Tanaka, K., Takechi, M., Asaoku, H., Dohy, H., & Kamada, N. (1992) · PubMed · Cited by 16
RAS gene mutations in multiple myeloma and related monoclonal gammopathies.
Matozaki, S., Nakagawa, T., Nakao, Y., & Fujita, T. (1991) · PubMed · Cited by 13
Does the product of the RB-1 locus have a cell cycle regulatory function?
Livingston, D. M., DeCaprio, J. A., & Ludlow, J. W. (1989) · PubMed · Cited by 4
Constitutively activated STAT3 in myeloma cells
Grigorieva, I. V., Chapman, M. S., & Epstein, J. (1996) · Cited by 1
Cited by
Raje, N., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,163
Self-citationBowman, T., Garcia, R., Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203527 · Cited by 1,743
“Previous studies have established the critical role of IL6 in proliferation and survival of human multiple myeloma cells (Hallek et al., 1998; Kishimoto et al., 1994).”
BackgroundCatlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80011-4 · Cited by 1,638
Iwakoshi, N. N., Lee, A.-H., Vallabhajosyula, P., Otipoby, K. L., Rajewsky, K., & Glimcher, L. H. (2003) · Nature Immunology · doi:10.1038/ni907 · Cited by 880
Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F. E., Tai, Y.-T., Treon, S. P., Lin, B., Schlossman, R. L., Richardson, P., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2943 · Cited by 875
Self-citation
Metadata
- Authors
- Hallek, M., Leif Bergsagel, P., & Anderson, K. C.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1998-01-01
- Volume
- 91
- Issue
- 1
- Pages
- 3-21
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1777794242
- Cited by
- 752
- References
- 265
- FWCI
- 36.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.